Pieris Pharmaceuticals (FRA:PI60) 3-Year Book Growth Rate : -21.30% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Pieris Pharmaceuticals 3-Year Book Growth Rate?

Pieris Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 was €16.34.

During the past 12 months, Pieris Pharmaceuticals's average Book Value per Share Growth Rate was 7.00% per year. During the past 3 years, the average Book Value per Share Growth Rate was -21.30% per year. During the past 5 years, the average Book Value per Share Growth Rate was -19.30% per year. During the past 10 years, the average Book Value per Share Growth Rate was 70.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 11 years, the highest 3-Year average Book Value per Share Growth Rate of Pieris Pharmaceuticals was 1073.50% per year. The lowest was -26.10% per year. And the median was 7.55% per year.

Competitive Comparison of Pieris Pharmaceuticals's 3-Year Book Growth Rate

For the Biotechnology subindustry, Pieris Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pieris Pharmaceuticals's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pieris Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Pieris Pharmaceuticals's 3-Year Book Growth Rate falls into.

Pieris Pharmaceuticals 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Pieris Pharmaceuticals (FRA:PI60) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Pieris Pharmaceuticals 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Pieris Pharmaceuticals's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Pieris Pharmaceuticals (FRA:PI60) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pieris Pharmaceuticals Inc (FRA:PI60) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

PIRS:USA PI6:Germany

Address

225 Franklin Street, 26th Floor, Boston, MA, USA, 02110

Website

https://www.pieris.com

Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm functions through the region of the United States.

Pieris Pharmaceuticals (FRA:PI60) Headlines

No Headlines